Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AERIFY-4: Long-term Safety and Tolerability of Itepekimab in COPD
NCT06208306Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 32
01
Overview
A Phase 3 trial of itepekimab in chronic obstructive pulmonary disease (COPD), sponsored by Sanofi. Started Jan 2024; status: completed.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06208306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06208306.